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Background: Yunnan has one of the oldest and the most severe human immunodeficiency virus (HIV) epidemics
in China. We conducted an observational study to evaluate the human papillomavirus (HPV) genotype distribution
in relation to cervical neoplastic disease risk among HIV-infected women in Yunnan.
Methods: We screened 301 HIV-infected non-pregnant women in Mangshi prefecture in Yunnan province. All consenting
participants underwent simultaneous and independent assessment by cervical cytology, colposcopy-histopathology,
and HPV genotyping. Unadjusted and multivariable-adjusted multinomial logistic regression analysis was conducted to
evaluate factors associated with single or multiple carcinogenic HPV genotypes.
Results: HPV genotypes were present in 43.5% (131/301) overall, and carcinogenic HPV genotypes were present in
37.5% (113/301) women. Among women with carcinogenic HPV genotypes, 80 (70.8% of 113) had a single
carcinogenic HPV type, while 33 (29.2%) women had multiple (2 or more) carcinogenic HPV types. Overall, the most
common carcinogenic HPV types were HPV52 (7.3%), HPV58 (6.6%), HPV18 (6.3%), HPV16 (6.0%), and HPV33 (5.3%). In
women with cervical precancerous lesions (i.e., high-grade squamous intraepithelial lesions [HSIL] on cytology or cervical
intraepithelial neoplasia grade 2 or worse [CIN2+] detected on colposcopy-histology), the most commonly detected
genotypes were HPV16 (28.6%), HPV52 (25.0%), HPV58 (17.9%), HPV18 (10.7%) and HPV31 (10.7%). Increasing age was an
independent risk factor associated with presence of single carcinogenic HPV types (adjusted odds ratio: 1.04, 95%CI:
1.01-1.07, p = 0.012) but not with the presence of multiple carcinogenic types in the multivariable-adjusted models.
Conclusions: As HIV-infected women continue to live longer on antiretroviral therapy in China, it will be increasingly
important to screen for, and prevent, HPV-associated cervical cancer in this population, especially given the wide
diversity and multiplicity of HPV genotypes.
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Invasive cervical cancer (ICC) is a leading cause of cancer
related morbidity and mortality afflicting women globally,
with over 527,000 annual incident cases and over 265,000
annual deaths [1]. An estimated 50,000 new cases are di-
agnosed and 38,000 women die annually due to ICC in
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unless otherwise stated.of the human papillomavirus (HPV) is the necessary etio-
logic factor for ICC. Of the 200+ identified HPV types, ap-
proximately 40 types can infect the human anogenital
tract, and HPV16 and 18 are associated with ~70% of ICC
cases [2].
Women with immunosuppressive conditions, such as
human immunodeficiency virus (HIV) infection/acquired
immunodeficiency syndrome (AIDS), have been shown to
have a higher prevalence of cervical HPV infection and
higher frequency of multiple HPV genotypes than women
from the general population [3]. The advent of antiretro-
viral therapy (ART) for treatment of HIV/AIDS hasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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women, yet has increased their risk for a prolonged period
of persistence of HPV infection, and consequently in-
creased risk of progression to cervical precancer and can-
cer [4]. HIV-infected women are 4–5 times more likely to
have ICC compared to HIV-uninfected women and ICC
has been classified as an AIDS-defining malignancy [5].
By the end of 2011, it was estimated that there were 7.8
million persons living with HIV in China [6]. The overall
national HIV prevalence estimates remains low (0.058%),
but the epidemic is concentrated in some geographical re-
gions such as Yunnan, a province in Southwestern China
with a high HIV burden, accounting for 34.8% of the esti-
mated number of cases nationally [7]. Due to limited avail-
ability and awareness of screening for cervical cancer, few
women are ever screened. Limited data is available on
the burden and genotypes of HPV among HIV-infected
women in this or other settings in China [8-10]. To ex-
pand the evidence in this area, we undertook a descrip-
tive epidemiology study to evaluate the presence and
distribution of HPV genotypes and correlated these with
cervical disease status in this population.
Results
Study population
At enrollment in the study, the mean age of the 301 HIV-
infected women was 34 years (standard deviation ±8.9). A
large majority (78.1%) were married or cohabiting with
their husband. About half (50.2%) had fewer than 4 years
of education (primary school or below), and under half of
them (44.5%) reported a family income ≤80.5 US Dollars
per month. Less than a quarter (24.3%) self-reported ever
having a sexually transmitted infection (STI). A majority
(62.5%) of participants reported their partners being HIV-
infected. One-sixth of the participants (15.9%) reported
exposure to smoking (inclusive of 2.7% current smokers,
4.7% former smokers, and 8.6% reporting second-hand
smoking exposure), about two-fifths (58.8%) reported con-
dom use with regular partners, more than two-thirds
(70.8%) had 2 or fewer lifetime sexual partners, and the
mean age of first sexual intercourse was 20 years (standard
deviation ±3.2). The mean CD4+ cell count was 571 cells/
μL, more than half (193/301, 64.1%) were taking ART, and
the mean duration of being on ART was 29 months.
Cytology results revealed 252/301 (83.7%) women with
‘negative for intraepithelial lesion or malignancy’ (NILM),
33 (11.0%) with atypical squamous cells of undetermined
significance (ASC-US), 11 (3.7%) with low-grade squamous
intraepithelial cells (LSIL), and 4 (1.3%) with high-grade
squamous intraepithelial cells (HSIL). One sample was
unsatisfactory for evaluation. Colposcopic-histopathologic
diagnosis revealed 251/301 (83.4%) women with no cer-
vical intraepithelial neoplasia (CIN), 22 (7.3%) with CIN1,
16 (5.3%) with CIN2, and 12 (4%) with CIN3 lesions. Thecomposite cytology-colposcopic-histopathological diagno-
sis (n = 301) showed no CIN (i.e., no CIN on colposcopy-
histology and NILM on cytology) in 251/301 (83.4%)
women, CIN1 (i.e., CIN1 on colposcopy-histology or
ASC-US/LSIL on cytology) in 22/301 (7.3%), CIN2 (i.e.,
CIN2 on colposcopy-histology or HSIL on cytology) in
16/301 (5.3%), and CIN3 (on colposcopy-histology) in 12/
301 (4.0%) women. Thus, CIN grade 2 or worse (i.e., CIN2+)
lesions were present in 28/301 (9.3%) women.
Distribution of HPV genotypes
Over two-fifths (131/301, 43.5%) of the HIV-infected
women in the study had presence of at least one HPV
genotype. A total of 21 out of the 23 HPV genotypes
identifiable by the HPV genotyping kit were detected
among the 131 participants in the study with HPV, in-
cluding all 13 carcinogenic HPV genotypes (HPV16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) (Table 1).
The five most common carcinogenic HPV genotypes
were HPV52 (7.3%), HPV58 (6.6%), HPV18 (6.3%),
HPV16 (6.0%), and HPV33 (5.3%). Among 131 women
with any HPV infection, 83 (63.4%) were infected with a
single HPV genotype, while 48 (36.6%) had multiple (≥2)
genotypes. Infection with two genotypes (dual infection)
accounted for almost two-thirds (32/48, 66.7%) of mul-
tiple infections, and HPV16 and HPV18 were the most
frequent dual infections (3/32, 9.4%).
A total of 113 out of 301 women (37.6%) had at least
one carcinogenic HPV type. Among these, 80 women
(70.8%) had a single carcinogenic HPV type infection,
while 33 (29.2%) women had more than 2 carcinogenic
HPV infections. Only 15/301 (5.0%) women were re-
ported to be infected with ‘possibly-carcinogenic’ HPV
types, and 34 (11.3%) women were detected with non-
carcinogenic types or types of unknown carcinogenicity.
HPV genotype prevalence by cervical diagnosis
The prevalence of HPV infection detected in all women,
and women with and without cervical neoplasia is given
in Table 1. The overall prevalence of HPV infection
(carcinogenic, ‘possibly carcinogenic’ and non/unknown-
carcinogenic HPV types) was 93/251 (37.1%) in women
without CIN, 14/22 (63.6%) in CIN1, and 24/28 (87.5%)
in women with CIN2+ lesions (p-for trend <0.001). The
most common carcinogenic HPV genotypes in individual
cervical disease categories were HPV18 (5.6%) in women
with no CIN, HPV35 (13.6%) in CIN1, and HPV16
(28.6%) in CIN2+. The trend for increasing prevalence of
HPV genotypes with increasing severity of cervical disease
grades was significant for carcinogenic HPV genotype
(p < 0.001), any single or multiple carcinogenic HPV (both
for p < 0.001), ‘possibly carcinogenic’ HPV (p = .035),
HPV16 (p < 0.001), as well as non-HPV16 carcinogenic
HPV (p < 0.001) (Table 1).
Table 1 Prevalence of HPV genotypes stratified by composite cytology-colposcopic-histopathological CIN diagnoses
HPV infection groupings/types Total
n (%)
No CIN (N = 251)
n (%)
CIN1 (N = 22)
n (%)
CIN2+ (N = 28)
n (%)
χ2trend p
Overall HPV infection 131(43.5) 93(37.1) 14(63.6) 24(85.7) 28.04 <0.001
Carcinogenic HPV infection
Single carcinogenic HPV type 80(26.6) 57(22.7) 7(31.8) 16(57.1) 26.19 <0.001
Multiple carcinogenic HPV types 33(11.0) 21(8.4) 4(18.2) 8(28.6) 19.59 <0.001
Possibly carcinogenic HPV infection 15(5.0) 8(3.2) 5(22.7) 2(7.1) 4.84 0.035a
Non-carcinogenic/unknown carcinogenic HPV infection 34(11.3) 26(10.4) 6(27.3) 2(7.1) 0.12 0.768a
Individual HPV genotypes:
Carcinogenic HPV genotypes
HPV16 18(6.0) 9(3.6) 1(4.6) 8(28.6) 23.71 <0.001a
HPV18 19(6.3) 14(5.6) 1(4.6) 4(14.3) 2.46 0.121a
HPV31 9(3.0) 4(1.6) 2(9.1) 3(10.7) 9.70 0.008a
HPV33 16(5.3) 11(4.4) 2(9.1) 3(10.7) 2.59 0.141a
HPV35 10(3.3) 7(2.8) 3(13.6) 0(0.0) 0.05 1.000a
HPV39 1(0.3) 1(0.4) 0(0.0) 0(0.0) 0.18 1.000a
HPV45 2(0.7) 2(0.8) 0(0.0) 0(0.0) 0.36 0.878a
HPV51 2(0.7) 2(0.8) 0(0.0) 0(0.0) 0.36 0.878a
HPV52 22(7.3) 14(5.6) 1(4.6) 7(25.0) 11.18 0.003a
HPV56 16(5.3) 14(5.6) 2(9.1) 0(0.0) 0.80 0.433a
HPV58 20(6.6) 13(5.2) 2(9.1) 5(17.9) 6.56 0.016a
HPV59 6(2.0) 4(1.6) 1(4.6) 1(3.6) 0.94 0.556a
HPV68 16(5.3) 14(5.6) 1(4.6) 1(3.6) 0.23 0.695a
Possibly carcinogenic HPV genotypes
HPV53 7(2.3) 4(1.6) 3(13.6) 0(0.0) 0.54 0.561a
HPV66 6(2.0) 3(1.2) 1(4.6) 2(7.1) 5.32 0.038a
HPV73 2(0.7) 1(0.4) 1(4.6) 0(0.0) 0.31 1.000a
HPV82 0(0.0) 0(0.0) 0(0.0) 0(0.0) - -
Non-carcinogenic/unknown carcinogenic HPV genotypes
HPV6 2(0.7) 1(0.4) 1(4.6) 0(0.0) 0.31 1.000a
HPV11 1(0.3) 0(0.0) 1(4.6) 0(0.0) 1.45 0.166a
HPV42 9(3.0) 6(2.4) 2(9.1) 1(3.6) 0.84 0.442a
HPV43 25(8.3) 20(8.0) 4(18.2) 1(3.6) 0.03 1.000a
HPV44 0(0.0) 0(0.0) 0(0.0) 0(0.0) - -
HPV83 3(1.0) 3(1.2) 0(0.0) 0(0.0) 0.54 0.847a
aFisher’s exact test. Statistically significant (p < 0.05) estimates are bolded and italicized. CIN, cervical intraepithelial neoplasia. CIN2+, cervical intraepithelial
neoplasia grade 2 or worse. HPV, human papillomavirus.
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duration
The age distribution of HPV infection prevalence in the
study population is depicted in Figure 1. After adjusting
for severity of cervical lesions, increasing age of partici-
pants was associated with higher detection of HPV in-
fections overall. In particular, this increase in proportion
across age categories was statistically significant for the
detections of any HPV, carcinogenic HPV, singlecarcinogenic HPV, and ‘possibly carcinogenic’ HPV ge-
notypes (p = 0.009, 0.001, 0.002, and 0.043 respectively).
The relative proportion of HPV infection by CD4+ cell
count categories, after adjusting for ART status, is
graphically displayed in Figure 2. In general, lower CD4+
cell counts were associated with higher detection of
HPV infections. However, the proportions varied signifi-
cantly (p < 0.05) only for the detections of carcinogenic
HPV and multiple carcinogenic HPV genotypes.
Figure 1 Age-specific prevalence of HPV infection among HIV-infected women in Yunnan, China. *p value for trend was <0.05, after
adjusting for cervical lesion. HPV, Human Papillomavirus. Carcinogenic HPV includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.
Possibly carcinogenic HPV includes HPV 53, 66, 73 and 82. With aging, p-value for trend for any type, carcinogenic HPV, single carcinogenic HPV
and possibly carcinogenic HPV were 0.009, 0.001, 0.002 and 0.043, respectively.
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(in months) on being on ART. Longer duration of being
on ART was associated with lower detection of HPV
infections. Statistically significant (p < 0.05) lower HPV
detections associated with categories of longer duration
on ART were observed for the groupings of carcinogenic
HPV and multiple carcinogenic HPV genotypes.
Risk factors of HPV infection
Table 2 reports the unadjusted and the multivariable-
adjusted associations of single and multiple carcinogenic
HPV infections with sociodemographic, behavioral, and
HIV-related covariates. In the unadjusted analysis, hav-
ing single carcinogenic HPV infection was directly asso-
ciated with age and having a cervical lesion (≥CIN1),
and inversely associated with CD4+ cell counts (Table 2)
while having multiple carcinogenic HPV infection was
directly associated only with having a cervical lesion
(≥CIN1). In the multivariable-adjusted multinomial lo-
gistic regression analysis, presence of single carcinogenic
HPV infection was independently associated with bothFigure 2 Prevalence of HPV infection by CD4+ cells count group amo
<0.05, after adjusting for ART therapy status. HPV, Human papillomavirus. C
59 and 68. Possibly carcinogenic HPV includes HPV 53, 66, 73 and 82. With
multiple carcinogenic HPV were 0.010 and 0.020, respectively.increasing age (adjusted odds ratio [AOR]: 1.04, 95%
confidence interval [CI]: 1.01-1.07, p = 0.012) and having
a cervical lesion (≥CIN1) (AOR: 5.37, 95% CI: 2.57-
11.23, p < 0.001) while presence of multiple carcinogenic
HPV infections were independently associated with having
a cervical lesion (≥CIN1) (AOR: 7.39, 95% CI: 2.98-18.29,
p < 0.001).
Discussion
Persistent infection with carcinogenic HPV is a necessary,
though not sufficient, cause for invasive cervical cancer.
HIV-infected women are more susceptible to HPV than
HIV-uninfected women. Within China, the HIV/AIDS
epidemic is diverse, with some of the highest rates in
southwest China, especially in Yunnan province [11].
The current study is the first study from China to pro-
vide a comprehensive assessment of the distribution of
HPV genotypes among HIV-infected women in Yunnan
using rigorously-ascertained cervical disease diagnoses.
To avoid unnecessary invasive diagnosis procedures and
increase the accuracy of CIN diagnosis than relying onng HIV-infected women in Yunnan, China. *p value for trend was
arcinogenic HPV includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
CD4+ cell count increasing, p-value for trend for carcinogenic HPV and
Figure 3 Prevalence of HPV infection by duration of receiving ART group among HIV-infected women in Yunnan, China. *p value for
trend of univariate analysis was <0.05. HPV, Human Papillomavirus. Carcinogenic HPV includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and
68. Possibly carcinogenic HPV includes HPV 53, 66, 73 and 82. ART, Antiretroviral Therapy. With increasing duration on ART, p-value for trend for
carcinogenic HPV and multiple carcinogenic HPV were 0.013 and 0.002, respectively.
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alone, our study combined both cytology results and
colposcopy-histologic diagnosis to compute composite
disease endpoints. Thus we maximized the detection of
cervical lesions, limited any selection bias, and increased
the representativeness of our findings. The results from our
cohort are therefore representative of HIV-infected women
who seek cervical cancer screening services in Yunnan and
our findings could add to the national and global data of
HPV distribution among HIV-infected populations.
Overall, at least one HPV genotype was detected in over
two-fifths of women and at least one carcinogenic HPV
genotype was present in over one-third of HIV-infected
women. The prevalence of any HPV infection (43.5%) was
almost three times higher than the corresponding rate
among the general (HIV-uninfected) population in China
[12], and the rate of carcinogenic HPV detection (37.5%)
was more than twice as high as corresponding rates re-
ported in studies conducted in the general Chinese popu-
lation [12]. These detection rates among HIV-infected
women in our study are comparable to that reported from
two other Chinese studies among HIV-infected women
[9,10]; yet these studies lacked the detailed cervical disease
assessment accomplished in our study.
The prevalence of HPV infection has ranged widely in
studies among HIV-infected women in Asia [6,8,13-18].
A global meta-analysis in 2006 reviewed 20 contempor-
aneous studies and demonstrated the overall prevalence
of HPV infection to be 36.3% among women without
cervical abnormalities, and increased with increased se-
verity of cervical disease [6]. Our cohort noted 37.1% of
women without CIN lesion were infected any HPV, and
carcinogenic HPV prevalence rate (31.1%) was similar to
that reported from Asia (31.1%), Europe (32.4%), North
America (31.4%), but lower than that from Africa
(56.6%) and South/Central America (57.3%) [6].
Consistent with meta-analysis of HPV types distribu-
tion among HIV-infected women [6], HPV16 was notthe most common type in the overall population in our
study. Some experts have hypothesized that HPV16 has
better evolutionary ability to escape the effects of im-
mune surveillance, while non-HPV16 genotypes are
often better controlled by immune response, such as
among women with competent immune systems (e.g.,
HIV-infected women with CD4 > 500/μL) [19,20]. In
women with progressively weakening immune systems
(i.e., with declining CD4+ cell counts), it is thought that
the immune control over non-HPV16 types is lost and
they appear with greater preponderance than in women
with competent immune systems [19,20]. Indeed, we did
observe an increase of non-HPV16 carcinogenic HPV
genotypes with progressively worsening immune status
reflected by lower CD4+ count categories (p-for trend =
0.029) and shorter duration of ART (p-for trend =
0.004), consistent with the hypothesized loss of immune
control over non-HPV16 types. However, HPV16 was still
the most commonly detected carcinogenic type among
women with cervical disease. Also, apart from non-
HPV16 carcinogenic HPV types, we found significant dif-
ferences regarding ART duration and CD4+ counts in any
HPV and any carcinogenic HPV (all p-for trend < 0.05).
Our results point to the need for further exploration of
differences in immune control between HPV16 and non-
HPV16 carcinogenic genotypes, and evaluating these asso-
ciations with cervical cancer risk. In addition, it may be
important to study the effect of early ART initiation on re-
duction in risk of carcinogenic HPV-induced neoplastic le-
sions, and if it differs by HPV genotypes involved. It will
also be important to study the etiologic significance of
concurrently present non/unknown-risk genotypes, some
of which such as HPV43 had higher prevalence than even
other carcinogenic HPV genotypes.
We noted that 29.2% of carcinogenic HPV positive
women were infected with multiple carcinogenic HPV ge-
notypes. This is similar to the rate of multiple HPV infec-
tions (32.2%) among carcinogenic HPV positive women in
Table 2 Risk factors of single and multiple carcinogenic HPV infection in unadjusted and multivariable-adjusted
multinomial logistic regression
Factor Total No carcinogenic
HPV infectiona
Single carcinogenic HPV Multiple carcinogenic HPV
N (%) n (%) n (%) Unadjusted OR
(95%CI)
p n (%) Unadjusted OR
(95%CI)
p
Unadjusted analysis
Age
(per year increase) 301(100.0) 188(100.0) 80(100.0) 1.03(1.00-1.06) 0.025 33(100.0) 1.02(0.98-1.01) 0.279
Married status
No-cohabiting 66(21.9) 39(20.7) 17(21.3) 1.00 10(30.3) 1.00
Married/cohabiting 235(78.1) 149(79.3) 63(78.8) 0.97(0.51-1.84) 0.926 23(69.7) 0.60(0.27-1.37) 0.226
Completed years of education
≤4 151(50.2) 98(52.1) 38(47.5) 1.00 15(45.5) 1.00
≥5 150(49.8) 90(47.9) 42(52.5) 1.20(0.71-2.03) 0.488 18(54.5) 1.31(0.62-2.75) 0.480
Family income (USD)
≤80.5 per month 134(44.5) 79(42.0) 37(46.3) 1.00 18(54.5) 1.00
>80.5 per month 167(55.5) 109(58.0) 43(53.8) 0.84(0.50-1.43) 0.523 15(45.5) 0.60(0.29-1.27) 0.184
Smoking
No 253(84.1) 157(83.5) 70(87.5) 1.00 26(78.8) 1.00
Yes 48(15.9) 31(16.5) 10(12.5) 0.72(0.34-1.56) 0.408 7(21.2) 1.36(0.54-3.42) 0.509
Patient’s partner infected with HIV
No 113(37.5) 70(37.2) 34(42.5) 1.00 9(27.3) 1.00
Yes 188(62.5) 118(62.8) 46(57.5) 0.80(0.47-1.37) 0.419 24(72.7) 1.58(0.70-3.60) 0.274
Age at first sex
≤18 years 95(31.6) 62(33.0) 24(30.0) 1.00 9(27.3) 1.00
>18 years 206(68.4) 126(67.0) 56(70.0) 1.15(0.65-2.02) 0.633 24(72.7) 1.31(0.58-2.99) 0.518
Lifetime sex partners
≤2 213(70.8) 137(72.9) 55(68.8) 1.00 21(63.6) 1.00
>2 88(29.2) 51(27.1) 25(31.3) 1.22(0.69-2.61) 0.494 12(36.4) 1.54(0.80-3.34) 0.281
History of STI
No 228(75.7) 136(72.3) 66(82.5) 1.00 26(78.8) 1.00
Yes 73(24.3) 52(27.7) 14(17.5) 0.56(0.29-1.07) 0.080 7(21.2) 0.70(0.29-1.72) 0.442
Condom use
No 124(41.2) 84(44.7) 26(32.5) 1.00 14(42.4) 1.00
Yes 177(58.8) 104(55.3) 54(67.5) 1.68(0.97-2.91) 0.065 19(57.6) 1.10(0.52-2.32) 0.810
Total number of pregnancies
<3 160(53.2) 101(53.7) 41(51.3) 1.00 18(54.5) 1.00
≥3 141(46.8) 87(46.3) 39(48.8) 1.10(0.65-1.87) 0.710 15(45.5) 0.97(0.46-2.03) 0.930
CD4+ cell count
(increase by 100/μL) 301(100.0) 188(100.0) 80(100.0) 0.89(0.80-0.99) 0.039 33(100.0) 0.91(0.78-1.06) 0.230
ART therapy
No 108(35.9) 71(37.8) 24(30.0) 1.00 13(39.4) 1.00
Yes 193(64.1) 117(62.2) 56(70.0) 1.42(0.81-2.48) 0.225 20(60.6) 0.93(0.44-1.99) 0.859
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Table 2 Risk factors of single and multiple carcinogenic HPV infection in unadjusted and multivariable-adjusted
multinomial logistic regression (Continued)
Factor Total No carcinogenic
HPV infectiona
Single carcinogenic HPV Multiple carcinogenic HPV
N (%) n (%) n (%) Unadjusted OR
(95%CI)
p n (%) Unadjusted OR
(95%CI)
p
Duration on ART (years)
No 108(35.9) 71(37.8) 24(30.0) 1.00 13(39.4) 1.00
<2 94(31.2) 51(27.1) 28(35.0) 1.62(0.85-3.12) 0.146 15(45.5) 1.61(0.70-3.67) 0.260
≥2 99(32.9) 66(35.1) 28(35.0) 1.26(0.66-2.38) 0.487 5(15.2) 0.41(0.14-1.22) 0.111
Cervical lesion
No 251(83.4) 173(92.0) 57(71.3) 1.00 21(63.6) 1.00
Yes 50(16.6) 15(8.0) 23(28.8) 4.65(2.27-9.52) <0.001 12(36.4) 6.59(2.72-15.95) <0.001
Total No carcinogenic
HPV infectiona
Single carcinogenic HPV Multiple carcinogenic HPV
N (%) n (%) n (%) Adjusted OR
(95%CI)
p n (%) Adjusted OR
(95%CI)
p
Multivariable-adjusted
analysisb
Age
(per year increase) 301(100.0) 188(100.0) 80(100.0) 1.04(1.01-1.07) 0.012 33(100.0) 1.03(0.99-1.08) 0.132
CD4+
(increase by 100 μL) 301(100.0) 188(100.0) 80(100.0) 1.00(1.00-1.00) 0.143 33(100.0) 1.00(1.00-1.00) 0.422
Cervical lesion
No 251(83.4) 173(92.0) 57(71.3) 1.00 21(63.6) 1.00
Yes 50(16.6) 15(8.0) 23(28.8) 5.37(2.57-11.23) <0.001 12(36.4) 7.39(2.98-18.29) <0.001
Statistically significant (p < 0.05) estimates are bolded and italicized. OR: Odds Ratio. 95%CI: Lower limits and upper limits of the 95% Confidence intervals. CIN,
cervical intraepithelial neoplasia. HPV, human papillomavirus. STI, sexually transmitted infection. ART, antiretroviral therapy.
Carcinogenic HPV includes HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68.
aNo carcinogenic HPV infection refers to absence of all 13 types of carcinogenic HPV.
bOnly factors that were statistically significant (p < 0.05) in the unadjusted analysis were included in the multivariable-adjusted analysis.
Zhang et al. Virology Journal 2014, 11:202 Page 7 of 10
http://www.virologyj.com/content/11/1/202the general population when using GP5+/GP6+ polymer-
ase chain reaction (PCR) assay as the HPV detection
method [21]. The proportion of multiple carcinogenic
HPV types was even higher (50%, 8/16) among women
with CIN2 or worse lesion. This high rate of multiple
HPV infections (consistent with the rates of 12%-87.5% in
previous studies in HIV-infected populations), confounds
the measurement of genotype-specific fractions attribut-
able to individual cervical disease categories [13,15,22]. A
higher prevalence of multiple HPV types may be due to
different reasons, including higher persistence and lower
clearance of HPV in the setting of HIV infection, contin-
ued sexual exposure to novel HPV types, reactivation of
latent HPV during periods of severe immune-suppression,
or may be due to high relative analytical sensitivity of the
PCR assay.
It was interesting to note that age was a significant fac-
tor only with the presence of single carcinogenic infec-
tion but not multiple carcinogenic infections in the
multivariable-adjusted analysis. While this lack ofstatistical association of age and multiple carcinogenic
infections is intriguing, it likely reflects the underpowered
nature of the study for evaluating this outcome, since we
only had 33 cases of multiple carcinogenic infections over-
all and only 8 among women with CIN2+ disease. Indeed,
we did not find any significant differences in multiple car-
cinogenic HPV infections relating to lower CD4+ cell
counts, sexual behaviors, or ART therapy. (Presence of
cervical lesions was a significant factor for both single and
multiple carcinogenic infection outcomes, as expected,
since HPV is a causative agent of cervical neoplastic
lesions).
We noted that there was no clear peak of carcinogenic
HPV prevalence in young (<30 years) women, unlike age-
specific HPV prevalence surveys in China and globally
[23,24]. There were no specific occupational or HIV-
related risk factor differences or characteristics that distin-
guished this cohort from other HIV-infected women in
Yunnan or China. Whether the atypical age-specific
curves are reflective of setting-specific cultural factors
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ual relations needs further exploration.
The currently available prophylactic HPV vaccines
offer protection against HPV16 and HPV18 and some
cross-protection to a few associated genotypes, and the
future nonavalent vaccine could extend the protection
against HPV 31/33/45/52/58. Although the vaccines
have been shown to be safe and immunogenic, there are
no studies yet on the efficacy of these vaccines among
HIV-infected women [25]. Hence, there is still no un-
equivocal recommendation to vaccinate all HIV-infected
women. In any case, given the high rates of HPV infec-
tion, a vast majority of HIV-infected women may already
be infected with types covered by the vaccine. Therefore,
screening and early detection of precancerous lesions
will continue to be important for HIV-infected women,
particularly as they live longer lives due to ART, and re-
main at continued risk for development and progression
of HPV-induced cervical lesions.
The strengths of our study included the choice of
combined cytological and colposcopy-histological diag-
nosis, to compute the final disease categorization for
women. This allowed for better disease ascertainment
than relying on the results of cytology or colposcopy-
histology alone. Our study also had several limitations.
Firstly, subtle immunosuppression could not be mea-
sured by the enumeration of circulating CD4+ cells. Sec-
ondly, this study was cross-sectional, so results only
could show an association but no evidence of causality.
Thirdly, some behavioral factors such as drug use and
commercial sex work were not captured in the question-
naire of our study, both of which are known to be sig-
nificant risk factors for HIV-infection for many women
in China, particularly in Yunnan. Finally, we note the ab-
sence of data on plasma HIV RNA data, nadir CD4
count, and duration of HIV infection while analyzing
risk factors as a limitation of the study.
Conclusions
In summary, in this cross-sectional study, we evaluated the
diverse distribution of HPV genotypes and factors associ-
ated with HPV infection among HIV-infected women in
Yunnan province. These results are similar to those re-
ported among HIV-infected women in countries with simi-
lar levels of the HIV epidemic. The diversity of HPV
genotypes in this population emphasizes the need for broad
spectrum (polyvalent) HPV vaccines for eventual primary
prevention, as well as the immediate necessity of regular
and vigilant screening for cervical disease in this population.
Methods
Study population
The study was conducted in a HIV-clinic in the Mangshi
prefecture of Yunnan province, where HIV-infectedwomen have been provided with free cervical cancer
screening services since March 2009. Study subjects were
recruited based on linkages with HIV voluntary counseling
and testing (VCT) centers and referrals of known HIV-
infected women from the provincial and prefecture-level
Center for Disease Control (CDC)-affiliated ART clinics.
The program staff, in close linkages with the CDC staff
and the federally-funded “Four Frees and One Care” pro-
gram that provided ART for HIV-infected women, was re-
sponsible for recruitment and retention of participants.
For our study, we selected a cohort of HIV-infected
women based on the following eligibility criteria: (i)
18 years of age or older (for informed consent); (ii) not
currently pregnant; (iii) no history of prior treatment for
cancer of the cervix; (iv) no history of hysterectomy; (v)
no prior history of cervical cancer screening; and (vi) men-
tally and physically fit for undergo a pelvic examination.
Participants were recruited regardless of CD4+ cell counts
or current status of receiving ART. The study protocol
was approved by the Institutional Review Boards at Can-
cer Institute and hospital, Chinese Academy of Medical
Sciences (CICAMS) and Vanderbilt University. All partici-
pants gave written, informed consent.
Study procedures
After detailed explanation of study procedures, written
informed consent was obtained. A structured question-
naire was used to collect socio-demographic information
and key bio-behavioral risk factors relevant to HIV/AIDS
or cervical cancer. All enrolled participants underwent a
complete external physical examination and venous
blood collection for CD4+ T-lymphocyte count. A pelvic
examination was performed with sample collection by
Ayre’s spatula and endocervical cytobrush (for HPV test-
ing and liquid-based cervical cytology). All participants
underwent visual screening and diagnostic colposcopy
by trained gynecologist. Colposcopically-directed cer-
vical biopsy, endocervical curettage (ECC), and loop
electrosurgical excision procedures (LEEP) were advised
and performed on consenting participants with clinical
evidence of cervical abnormalities.
Biopsy specimens were processed and interpreted by
consulting pathologists affiliated with the Yunnan Cancer
Hospital. Colposcopy and histology results were reported
as per the Richart cervical intraepithelial neoplasia [CIN]
grading system [26] and cervical cytology results were re-
ported as per revised (2001) Bethesda classification [27].
The final diagnosis for each woman was based on combin-
ing the results of the worst diagnosis on both colposcopy/
histology and cytology: ‘No CIN’ (normal colposcopy/hist-
ology and cytology results of ‘negative for intraepithelial
lesions of malignancy’ [NILM]), ‘CIN1’ (CIN1 lesions on
colposcopy/histology or cervical cytology results of either
atypical squamous cells of undetermined significance
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[LSIL], ‘CIN2+’ (CIN2 or CIN3 on colposcopy/histology or
high-grade squamous intraepithelial cells [HSIL] on cer-
vical cytology).
We performed HPV genotyping on cervical specimens
using polymerase chain reaction (PCR)-based amplifica-
tion and commercial DNA-chip technology kit (Yaneng
Bioscience (Shenzhen) Co. Ltd, P20120401), an SFDA-
approved assay that has been extensively used in the past
[28]. The kit could amplify and detect the presence of 23
HPV types: 6, 11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45,
51, 53, 52, 56, 58, 59, 66, 68, 73, 82, and 83. The thresh-
old for detection of HPV was 1.0 × 103 viral copies/μL.
According to Bouvard classification [2], HPV genotypes
groups were carcinogenic HPV (including HPV16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), ‘possibly car-
cinogenic’ HPV (including HPV53, 66, 73 and 82) and
non-carcinogenic HPV/HPV of unknown carcinogenicity
(including HPV6, 11, 42, 43, 44 and 83).Statistical analyses
The statistical analysis was conducted using IBM SPSS
17.0. The distribution of HPV infection and genotypes
were presented as proportion. Chi-square tests were
used for assessing the relationship between the distribu-
tion of HPV genotypes and different grades of cervical
disease. Unadjusted and multivariable-adjusted multi-
nomial logistic regression were used to assess the effect
of socio-demographic, sexual, reproductive and HIV-
infection related characteristics on the presence of single
and multiple types of carcinogenic HPV, and adjusted
odds ratios (AOR) and 95% confidence intervals (95%CI)
of factors independently associated with single and mul-
tiple carcinogenic HPV infection among HIV-infected
women were calculated. A two-tailed p-value of <0.05 was
considered significant.Ethics statement
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